444 related articles for article (PubMed ID: 18381960)
21. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.
Allegrini G; Goulette FA; Darnowski JW; Calabresi P
Cancer Chemother Pharmacol; 2004 Mar; 53(3):261-6. PubMed ID: 14658007
[TBL] [Abstract][Full Text] [Related]
22. The antitumor effect of a novel differentiation inducer, 2, 2-Bis (4-(4-amino-3-hydroxyphenoxy) phenyl) adamantane (DPA), in combinatory therapy on human colon cancer.
Wang JJ; Lee JY; Chen YC; Chern YT; Chi CW
Int J Oncol; 2006 Apr; 28(4):1003-12. PubMed ID: 16525652
[TBL] [Abstract][Full Text] [Related]
23. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.
Ravi R; Jain AJ; Schulick RD; Pham V; Prouser TS; Allen H; Mayer EG; Yu H; Pardoll DM; Ashkenazi A; Bedi A
Cancer Res; 2004 Dec; 64(24):9105-14. PubMed ID: 15604280
[TBL] [Abstract][Full Text] [Related]
24. Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5.
van Geelen CM; Pennarun B; Le PT; de Vries EG; de Jong S
BMC Cancer; 2011 Jan; 11():39. PubMed ID: 21272366
[TBL] [Abstract][Full Text] [Related]
25. Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells.
Motwani M; Sirotnak FM; She Y; Commes T; Schwartz GK
Cancer Res; 2002 Jul; 62(14):3950-5. PubMed ID: 12124325
[TBL] [Abstract][Full Text] [Related]
26. Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo.
Pohl M; Stricker I; Schoeneck A; Schulmann K; Klein-Scory S; Schwarte-Waldhoff I; Hasmann M; Tannapfel A; Schmiegel W; Reinacher-Schick A
J Cancer Res Clin Oncol; 2009 Oct; 135(10):1377-86. PubMed ID: 19340455
[TBL] [Abstract][Full Text] [Related]
27. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
Prewett MC; Hooper AT; Bassi R; Ellis LM; Waksal HW; Hicklin DJ
Clin Cancer Res; 2002 May; 8(5):994-1003. PubMed ID: 12006511
[TBL] [Abstract][Full Text] [Related]
28. TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth.
Derosier LC; Vickers SM; Zinn KR; Huang Z; Wang W; Grizzle WE; Sellers J; Stockard CR; Zhou T; Oliver PG; Arnoletti P; Lobuglio AF; Buchsbaum DJ
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3198-207. PubMed ID: 18089714
[TBL] [Abstract][Full Text] [Related]
29. Treatment of small cell lung cancer with TRA-8 in combination with cisplatin and radiation.
Bonner JA; Willey CD; Yang ES; Dobelbower MC; Sanford LL; Bright SJ; Buchsbaum DJ; Raisch KP
Radiother Oncol; 2011 Oct; 101(1):183-9. PubMed ID: 21722984
[TBL] [Abstract][Full Text] [Related]
30. High-resolution single-photon emission computed tomography and X-ray computed tomography imaging of Tc-99m-labeled anti-DR5 antibody in breast tumor xenografts.
Kim H; Chaudhuri TR; Buchsbaum DJ; Wang D; Zinn KR
Mol Cancer Ther; 2007 Mar; 6(3):866-75. PubMed ID: 17363481
[TBL] [Abstract][Full Text] [Related]
31. Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5.
Fiveash JB; Gillespie GY; Oliver PG; Zhou T; Belenky ML; Buchsbaum DJ
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):507-16. PubMed ID: 18474311
[TBL] [Abstract][Full Text] [Related]
32. 2-methoxy-5-amino-N-hydroxybenzamide sensitizes colon cancer cells to TRAIL-induced apoptosis by regulating death receptor 5 and survivin expression.
Stolfi C; Caruso R; Franzè E; Rizzo A; Rotondi A; Monteleone I; Fantini MC; Pallone F; Monteleone G
Mol Cancer Ther; 2011 Oct; 10(10):1969-81. PubMed ID: 21817114
[TBL] [Abstract][Full Text] [Related]
33. Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity.
Kaliberov SA; Chiz S; Kaliberova LN; Krendelchtchikova V; Della Manna D; Zhou T; Buchsbaum DJ
Cancer Gene Ther; 2006 Feb; 13(2):203-14. PubMed ID: 16082379
[TBL] [Abstract][Full Text] [Related]
34. Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis.
Abdulghani J; Allen JE; Dicker DT; Liu YY; Goldenberg D; Smith CD; Humphreys R; El-Deiry WS
PLoS One; 2013; 8(9):e75414. PubMed ID: 24086526
[TBL] [Abstract][Full Text] [Related]
35. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer.
Van Hattum AH; Pinedo HM; Schlüper HM; Hausheer FH; Boven E
Int J Cancer; 2000 Oct; 88(2):260-6. PubMed ID: 11004678
[TBL] [Abstract][Full Text] [Related]
36. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5.
Adams C; Totpal K; Lawrence D; Marsters S; Pitti R; Yee S; Ross S; Deforge L; Koeppen H; Sagolla M; Compaan D; Lowman H; Hymowitz S; Ashkenazi A
Cell Death Differ; 2008 Apr; 15(4):751-61. PubMed ID: 18219321
[TBL] [Abstract][Full Text] [Related]
37. Synergistic antitumor activity of capecitabine in combination with irinotecan.
Cao S; Durrani FA; Rustum YM
Clin Colorectal Cancer; 2005 Jan; 4(5):336-43. PubMed ID: 15663838
[TBL] [Abstract][Full Text] [Related]
38. Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.
Britten CD; Hilsenbeck SG; Eckhardt SG; Marty J; Mangold G; MacDonald JR; Rowinsky EK; Von Hoff DD; Weitman S
Cancer Res; 1999 Mar; 59(5):1049-53. PubMed ID: 10070962
[TBL] [Abstract][Full Text] [Related]
39. Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancer.
Arafat W; Zhou T; Naoum GE; Buchsbaum DJ
J Egypt Natl Canc Inst; 2015 Dec; 27(4):205-15. PubMed ID: 26385392
[TBL] [Abstract][Full Text] [Related]
40. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.
Zhou L; Wang W; Dicker DT; Humphreys RC; El-Deiry WS
Cancer Biol Ther; 2011 Aug; 12(4):335-48. PubMed ID: 21785270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
